Abstract
Tetracyclines are a class of antibiotics which could play a therapeutic role in several neurological disorders. Minocycline, extensively studied in animal models, decreased the size of ischaemic and haemorrhagic infarct. In Parkinsons disease models minocycline protected the nigrostriatal pathway, and in Huntingtons disease and motoneuron disease models delayed the progression of disease extending the lifespan. Finally, in human diseases such as stroke and multiple sclerosis tetracyclines seem to play some neuroprotective role. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis, and the suppression of reactive oxygen species production. These mechanisms are involved in the pathogenesis of several neurodegenerative disorders. Several reports showed that minocycline reduced mitochondrial Ca2+ uptake, stabilized mitochondrial membranes, and reduced the release into the cytoplasm of apoptotic factors. Other effects include upregulation of mitochondrial bcl-2 (an antiapoptotic protein), direct scavenging of reactive oxygen species, and inhibition of mitogen activated protein kinases. It is still unclear which of these mechanisms plays the pivotal role in neuroprotective properties of tetracyclines. The anti-apoptotic effect of tetracyclines probably involves the mitochondrion. The major target for tetracyclines in neurodegeneration could lie within the complex network that links mitochondria, oxidative stress, poly (ADP-ribose) polymerase-1 and apoptosis. Here, we review the neuroprotective effects of tetracyclines in animal models and in human disease, and we focus on their possible mechanism(s) of action, with special regard to mitochondrial dysfunction in neurodegeneration.
Keywords: Mitochondria, Neurodegeneration, PARP-1, ROS, Tetracyclines
CNS & Neurological Disorders - Drug Targets
Title: Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
Volume: 8 Issue: 3
Author(s): D. Orsucci, V. Calsolaro, M. Mancuso and G. Siciliano
Affiliation:
Keywords: Mitochondria, Neurodegeneration, PARP-1, ROS, Tetracyclines
Abstract: Tetracyclines are a class of antibiotics which could play a therapeutic role in several neurological disorders. Minocycline, extensively studied in animal models, decreased the size of ischaemic and haemorrhagic infarct. In Parkinsons disease models minocycline protected the nigrostriatal pathway, and in Huntingtons disease and motoneuron disease models delayed the progression of disease extending the lifespan. Finally, in human diseases such as stroke and multiple sclerosis tetracyclines seem to play some neuroprotective role. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis, and the suppression of reactive oxygen species production. These mechanisms are involved in the pathogenesis of several neurodegenerative disorders. Several reports showed that minocycline reduced mitochondrial Ca2+ uptake, stabilized mitochondrial membranes, and reduced the release into the cytoplasm of apoptotic factors. Other effects include upregulation of mitochondrial bcl-2 (an antiapoptotic protein), direct scavenging of reactive oxygen species, and inhibition of mitogen activated protein kinases. It is still unclear which of these mechanisms plays the pivotal role in neuroprotective properties of tetracyclines. The anti-apoptotic effect of tetracyclines probably involves the mitochondrion. The major target for tetracyclines in neurodegeneration could lie within the complex network that links mitochondria, oxidative stress, poly (ADP-ribose) polymerase-1 and apoptosis. Here, we review the neuroprotective effects of tetracyclines in animal models and in human disease, and we focus on their possible mechanism(s) of action, with special regard to mitochondrial dysfunction in neurodegeneration.
Export Options
About this article
Cite this article as:
Orsucci D., Calsolaro V., Mancuso M. and Siciliano G., Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease, CNS & Neurological Disorders - Drug Targets 2009; 8 (3) . https://dx.doi.org/10.2174/187152709788680689
DOI https://dx.doi.org/10.2174/187152709788680689 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Preface: A New Era of Nanoimmunology
Current Pharmaceutical Biotechnology The Effect of Statins on the Differentiation and Function of Central Nervous System Cells
Current Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia
Current HIV Research CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Cannabis Use, First-Episode Psychosis, and Schizotypy: A Summary and Synthesis of Recent Literature
Current Psychiatry Reviews Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design A Resurrection of 7-MEOTA: A Comparison with Tacrine
Current Alzheimer Research Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages
Current Topics in Medicinal Chemistry Phytochemical, Geographical, and Pharmacological Retrospect of Genus <i>Torilis</i>
Current Topics in Medicinal Chemistry Sida cordifolia, a Traditional Herb in Modern Perspective – A Review
Current Traditional Medicine Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design